NGS Revenue Outpaces Market with 24% Growth and Now Fuels One-Third of Clinical Sales
NeoGenomics, Inc. (NASDAQ:NEO) delivered third quarter 2025 results showing rapid expansion in Next Generation Sequencing (NGS) services—a standout 24% increase from the prior year, well above broader market growth rates for this technology. NGS now comprises nearly one-third of the company’s clinical revenue, reinforcing the strategy to focus on higher-value diagnostics in oncology.
Record Revenue Driven by Clinical Volume and Shift to High-Value Testing
Consolidated revenue hit a record $188 million, up 12% year-over-year, as clinical test volume rose 15%. The increase was further fueled by a 3% gain in average revenue per clinical test (up to $476), signaling continued demand for premium services. The following table highlights quarterly clinical trends:
| Metric | Q3 2025 | Q3 2024 | % Change |
|---|---|---|---|
| Clinical Tests Performed (incl. Pathline) | 360,774 | 314,564 | 14.7% |
| Average Revenue/Test (incl. Pathline) | $476 | $463 | 2.8% |
| NGS Revenue Growth (YoY) | 24% | ||
Adjusted Profit Remains Positive, Margins Slightly Contract as Cost Pressures Mount
While gross profit grew 7% to $80.4 million, cost pressures and investments led to a gross profit margin of 42.8%, down from 44.6% a year ago. Adjusted EBITDA remained positive at $12.2 million, despite a 9% year-over-year decrease, reflecting operational resilience amid spending on strategic growth and higher labor costs. The company’s focus on higher-value NGS tests supported both revenue mix and resilience against broader market headwinds.
| Key Financials | Q3 2025 | Q3 2024 | % Change |
|---|---|---|---|
| Consolidated Revenue | $188M | $168M | 12% |
| Gross Profit Margin | 42.8% | 44.6% | -1.8 pts |
| Adjusted EBITDA | $12.2M | $13.4M | -9% |
Guidance Reaffirmed: Full-Year Revenue Seen Up to $726 Million
NeoGenomics reaffirmed its 2025 guidance, projecting revenue between $720 million and $726 million—a year-over-year increase of up to 10%. While the company anticipates a GAAP net loss for the year, adjusted EBITDA is expected to range from $41 million to $44 million, underscoring a focus on operational improvement despite short-term margin pressures. The company's strong cash and marketable securities position of $164 million supports its growth initiatives.
| 2025 Guidance | Low | High | YoY % Change |
|---|---|---|---|
| Revenue | $720M | $726M | 9% - 10% |
| Net Loss (GAAP) | $(116M) | $(108M) | +37% - +47% |
| Adjusted EBITDA | $41M | $44M | +3% - +10% |
Market Position: Broad Test Menu and Customer-Centric Model Create Momentum for 2026
CEO Tony Zook emphasized the company’s differentiation via a comprehensive oncology-focused menu and presence in the community hospital setting, where most cancer care is delivered. Ongoing investments in therapy selection and minimal residual disease (MRD) testing—both high-growth areas with unmet needs—position NeoGenomics for continued clinical and commercial expansion into next year. The reaffirmed guidance suggests confidence in further NGS penetration and resilience against ongoing margin headwinds.
Key Takeaways: Rapid NGS Adoption and Resilient Clinical Revenue Underpin Optimism
For investors and market watchers, NeoGenomics’ Q3 2025 report signals robust core business strength anchored by NGS outperformance and resilient clinical demand, despite pressure on margins and bottom line. The strategic shift toward high-value, precision oncology diagnostics looks likely to drive growth as the company moves into 2026, even as cost management and capital allocation remain in focus.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI